The letter argues against a proposal to let the U.S. Health and Human Services Secretary use the purchasing power of Medicare to negotiate with pharmaceutical companies for lower prices on prescription drugs used by Medicare patients through the Part D program.
FORBES: Manufacturing Consent: Pharma Lobbying Letter to Congress Lists Opponents as Supporters